Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Thomas Chen acquired 12,757 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $5.49 per share, with a total value of $70,035.93. Following the transaction, the chief executive officer owned 13,705 shares in the company, valued at $75,240.45. The trade was a 1,345.68% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Neonc Technologies Stock Down 1.5%
Shares of NASDAQ:NTHI traded down $0.07 during midday trading on Thursday, hitting $4.56. The stock had a trading volume of 190,264 shares, compared to its average volume of 96,200. Neonc Technologies Holdings, Inc. has a 1 year low of $3.01 and a 1 year high of $12.99. The stock has a 50 day moving average price of $4.14 and a two-hundred day moving average price of $5.95.
Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).
Analyst Upgrades and Downgrades
View Our Latest Research Report on NTHI
Institutional Investors Weigh In On Neonc Technologies
Several institutional investors have recently modified their holdings of NTHI. Barclays PLC grew its stake in Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after acquiring an additional 8,982 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Neonc Technologies during the fourth quarter worth about $124,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Neonc Technologies in the fourth quarter valued at about $126,000. Royal Bank of Canada purchased a new stake in shares of Neonc Technologies in the first quarter valued at about $247,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Neonc Technologies in the second quarter valued at approximately $126,000.
Neonc Technologies Company Profile
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Featured Articles
- Five stocks we like better than Neonc Technologies
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
